

Akonni pre-clinical results on rapid, low-cost array moves company closer to commercialization for its infectious disease test portfolio

I-Micronews

Akonni Biosystems announces results from three pre-clinical studies that contribute to the body of clinical evidence that verifies the efficacy of Akonni's TruDiagnosis molecular diagnostics (MDx) platform. Akonni TruArray® Tests are designed to fulfill market needs for mid-multiplex molecular diagnostics (tens to hundreds of molecular markers) deployed in near point-of-care settings, at a similar cost to conventional culture tests and with the accuracy and speed of gold-standard low-multiplex approaches.

These studies, including those for methicillin-resistant *Staphylococcus aureus* (MRSA), multi-drug resistant *Mycobacterium tuberculosis* (MDR-TB), and influenza subtyping, were funded and developed over the past six years by carefully leveraging more than \$45M in private and public funding from the National Institutes of Health (NIH), Centers for Disease Control (CDC), National Science Foundation (NSF), and the Department of Defense (DOD).

"The development of highly extensible, mid-multiplex, low-cost diagnostics for use in near-point-of-care settings is critical for mitigating the uncontrolled spread of disease, especially in global health settings," says **Kevin Banks, Ph.D.**, Vice President Strategic Development at Akonni Biosystems.

Source URL (retrieved on 01/28/2015 - 11:56am):

http://www.mdtmag.com/news/2013/01/akonni-pre-clinical-results-rapid-low-cost-array-moves-company-closer-commercialization-its-infectious-disease-test-portfolio?qt-video_of_the_day=0